Maheshwari A, Gibreel A, Siristatidis CS, Bhattacharya S. Gonadotrophin-releasing hormone agonist protocols for pituitary suppression in assisted reproduction. Cochrane Database Syst. Rev. 8,CD006919(2011).
Hughes EG, Fedorkow DM, Daya S, Sagle MA, Van de Koppel P, Collins JA. The routine use of gonadotropin-releasing hormone agonists prior to in vitro fertilization and gamete intrafallopian transfer: a meta-analysis of randomized controlled trials. Fertil. Steril. 58(5),888–896(1992).
Jenkins J. The influence, development and management of functional ovarian cysts during IVF cycles. J. Br. Fertil. Soc. 1(2),132–136(1996).
Loutradis D, Drakakis P, Vomvolaki E, Antsaklis A. Different ovarian stimulation protocols for women with diminished ovarian reserve. J. Assist. Reprod. Genet. 24(12),597–611(2007).
Surrey ES. Management of the poor responder: the role of GnRH agonists and antagonists. J. Assist. Reprod. Genet. 24(12),613–619(2007).
Kahraman K, Berker B, Atabekoglu CS et al. Microdose gonadotropin-releasing hormone agonist flare-up protocol versus multiple dose gonadotropin-releasing hormone antagonist protocol in poor responders undergoing intracytoplasmic sperm injection-embryo transfer cycle. Fertil. Steril. 91(6), 2437–2444(2009).
Olivennes F, Fanchin R, Bouchard P et al. The single or dual administration of the gonadotropin-releasing hormone antagonist cetrorelix in an in vitro fertilization–embryo transfer program. Fertil. Steril. 62(3),468–476(1994).
Al-Inany HG, Youssef MA, Aboulghar M et al. Gonadotrophin-releasing hormone antagonists for assisted reproductive technology. Cochrane Database Syst. Rev. 5,CD001750(2011).
Huirne JA, Homburg R, Lambalk CB. Are GnRH antagonists comparable to agonists for use in IVF? Hum. Reprod. 22(11),2805–2813(2007).
Griesinger G, Venetis CA, Marx T, Diedrich K, Tarlatzis BC, Kolibianakis EM. Oral contraceptive pill pretreatment in ovarian stimulation with GnRH antagonists for IVF: a systematic review and meta-analysis. Fertil. Steril. 90(4),1055–1063(2008).
Lee TH, Wu MY, Chen HF, Chen MJ, Ho HN, Yang YS. Ovarian response and follicular development for single-dose and multiple-dose protocols for gonadotropin-releasing hormone antagonist administration. Fertil. Steril. 83(6),1700–1707(2005).
Ng EH, Ho PC. Use of gonadotrophin releasing hormone (GnRH) antagonist (cetrotide) during ovarian stimulation for in vitro fertilization treatment: multiple doses and single dose. J. Obstet. Gynecol. Res. 27(5),261–265(2001).
Al-Inany H, Aboulghar MA, Mansour RT, Serour GI. Optimizing GnRH antagonist administration: meta-analysis of fixed versus flexible protocol. Reprod. Biomed. Online 10(5),567–570(2005).
Al-Inany H, Aboulghar M. GnRH antagonist in assisted reproduction: a Cochrane review. Hum. Reprod. 17(4), 874–885(2002).
Griesinger G, Felberbaum R, Diedrich K. GnRH antagonists in ovarian stimulation: a treatment regimen of clinicians’ second choice? Data from the German National IVF Registry. Hum. Reprod. 20(9),2373–2375(2005).
Al-Inany H, Aboulghar M. Gonadotrophin-releasing hormone antagonists for assisted conception. Cochrane Database Syst. Rev. 4,CD001750(2001).
Al-Inany HG, Abou-Setta AM, Aboulghar M. Gonadotrophin-releasing hormone antagonists for assisted conception. Cochrane Database Syst. Rev. 3,CD001750(2006).
van Wely M, Kwan I, Burt AL et al. Recombinant versus urinary gonadotrophin for ovarian stimulation in assisted reproductive technology cycles. Cochrane Database Syst. Rev. 2, CD005354(2011).
Youssef MA, Al-Inany HG, Aboulghar M, Mansour R, Abou-Setta AM. Recombinant versus urinary human chorionic gonadotrophin for final oocyte maturation triggering in IVF and ICSI cycles. Cochrane Database Syst. Rev. 4,CD003719(2011).
Afnan M. Identifying real differences in live birth rates between HMG and rFSH in IVF. Reprod. Biomed. Online 18(Suppl. 2),25–30(2009).
European and Israeli Study Group on Highly Purified Menotropin versus Recombinant Follicle-Stimulating Hormone. Efficacy and safety of highly purified menotropin versus recombinant follicle-stimulating hormone in in vitro fertilization/intracytoplasmic sperm injection cycles: a randomized, comparative trial. Fertil. Steril. , 78(3), 520(2002).
Andersen AN, Devroey P, Arce JC. Clinical outcome following stimulation with highly purified hMG or recombinant FSH in patients undergoing IVF: a randomized assessor-blind controlled trial. Hum. Reprod. 21(12),3217–3227(2006).
Seyhan A, Ata B. The role of corifollitropin a in controlled ovarian stimulation for IVF in combination with GnRH antagonist. Int. J. Womens. Health 3,243–255(2011).
Croxtall JD, McKeage K. Corifollitropin a: a review of its use in controlled ovarian stimulation for assisted reproduction. BioDrugs 25(4),243–254(2011).
Mahmoud Youssef MA, van Wely M, Aboulfoutouh I, El-Khyat W, van der Veen F, Al-Inany H. Is there a place for corifollitropin a in IVF/ICSI cycles? A systematic review and meta-analysis. Fertil. Steril. 97(4), 876–885(2012).
Fauser BC, Alper MM, Ledger W, Schoolcraft WB, Zandvliet A, Mannaerts BM; Engage Investigators. Pharmacokinetics and follicular dynamics of corifollitropin a versus recombinant FSH during ovarian stimulation for IVF. Reprod. Biomed. Online 21(5), 593–601(2010).
Shoham Z. The clinical therapeutic window for luteinizing hormone in controlled ovarian stimulation. Fertil. Steril. 77(6),1170–1177(2002).
le Cotonnec JY, Loumaye E, Porchet HC, Beltrami V, Munafo A. Pharmacokinetic and pharmacodynamic interactions between recombinant human luteinizing hormone and recombinant human follicle-stimulating hormone. Fertil. Steril. 69(2), 201–209(1998).
Shoham Z, Balen A, Patel A, Jacobs HS. Results of ovulation induction using human menopausal gonadotropin or purified follicle-stimulating hormone in hypogonadotropic hypogonadism patients. Fertil. Steril. 56(6), 1048–1053(1991).
Kolibianakis EM, Collins J, Tarlatzis B, Papanikolaou E, Devroey P. Are endogenous LH levels during ovarian stimulation for IVF using GnRH analogues associated with the probability of ongoing pregnancy? A systematic review. Hum. Reprod. Update 12(1),3–12(2006).
Humaidan P, Bungum M, Bungum L, Yding Andersen C. Effects of recombinant LH supplementation in women undergoing assisted reproduction with GnRH agonist down-regulation and stimulation with recombinant FSH: an opening study. Reprod. Biomed. Online 8(6),635–643(2004).
Marrs R, Meldrum D, Muasher S, Schoolcraft W, Werlin L, Kelly E. Randomized trial to compare the effect of recombinant human FSH (follitropin a) with or without recombinant human LH in women undergoing assisted reproduction treatment. Reprod. Biomed. Online 8(2), 175–182(2004).
Ferraretti AP, Gianaroli L, Magli MC, D’angelo A, Farfalli V, Montanaro N. Exogenous luteinizing hormone in controlled ovarian hyperstimulation for assisted reproduction techniques. Fertil. Steril. 82(6), 1521–1526(2004).
De Placido G, Alviggi C, Perino A et al. Italian Collaborative Group on Recombinant Human Luteinizing Hormone. Recombinant human LH supplementation versus recombinant human FSH (rFSH) step-up protocol during controlled ovarian stimulation in normogonadotrophic women with initial inadequate ovarian response to rFSH. A multicentre, prospective, randomized controlled trial. Hum. Reprod. 20(2), 390–396(2005).
Sauer MV, Thornton MH 2^nd, Schoolcraft W, Frishman GN. Comparative efficacy and safety of cetrorelix with or without mid-cycle recombinant LH and leuprolide acetate for inhibition of premature LH surges in assisted reproduction. Reprod. Biomed. Online 9(5),487–493(2004).
Griesinger G, Shapiro DB. Luteinizing hormone add-back: is it needed in controlled ovarian stimulation, and if so, when? J. Reprod. Med. 56(7–8), 279–300(2011).
Levi-Setti PE, Cavagna M, Bulletti C. Recombinant gonadotrophins associated with GnRH antagonist (cetrorelix) in ovarian stimulation for ICSI: comparison of r-FSH alone and in combination with r-LH. Eur. J. Obstet. Gynecol. Reprod. Biol. 126(2), 212–216(2006).
Bosch E, Labarta E, Crespo J, Simón C, Remohí J, Pellicer A. Impact of luteinizing hormone administration on gonadotropin-releasing hormone antagonist cycles: an age-adjusted analysis. Fertil. Steril. 95(3), 1031–1036(2011).
Fauser BC, Devroey P. Why is the clinical acceptance of gonadotropin-releasing hormone antagonist cotreatment during ovarian hyperstimulation for in vitro fertilization so slow? Fertil. Steril. 83(6), 1607–1611(2005).
Edwards RG, Lobo R, Bouchard P. Time to revolutionize ovarian stimulation. Hum. Reprod. 11(5), 917–919(1996).
Nargund G, Fauser BC, Macklon NS, Ombelet W, Nygren K, Frydman R; Rotterdam ISMAAR Consensus Group on Terminology for Ovarian Stimulation for IVF. The ISMAAR proposal on terminology for ovarian stimulation for IVF. Hum. Reprod. 22(11),2801–2804(2007).
Fauser BC, Nargund G, Andersen AN et al. Mild ovarian stimulation for IVF: 10 years later. Hum. Reprod. 25(11),2678–2684(2010).
Verberg MF, Eijkemans MJ, Heijnen EM et al. Why do couples drop-out from IVF treatment? A prospective cohort study. Hum. Reprod. 23(9),2050–2055(2008).
Polinder S, Heijnen EM, Macklon NS, Habbema JD, Fauser BJ, Eijkemans MJ. Cost–effectiveness of a mild compared with a standard strategy for IVF: a randomized comparison using cumulative term live birth as the primary endpoint. Hum. Reprod. 23(2),316–323(2008).
Heijnen EM, Eijkemans MJ, De Klerk C et al. A mild treatment strategy for in vitro fertilisation: a randomised non-inferiority trial. Lancet 369(9563),743(2007).
Pierce JG, Parsons TF. Glycoprotein hormones: structure and function. Annu. Rev. Biochem. 50, 465–495(1981).
Zegers-Hochschild F, Fernández E, Mackenna A, Fabres C, Altieri E, Lopez T. The empty follicle syndrome: a pharmaceutical industry syndrome. Hum. Reprod. 10(9), 2262–2265(1995).
Beckers NG, Macklon NS, Eijkemans MJ et al. Nonsupplemented luteal phase characteristics after the administration of recombinant human chorionic gonadotropin, recombinant luteinizing hormone, or gonadotropin-releasing hormone (GnRH) agonist to induce final oocyte maturation in in vitro fertilization patients after ovarian stimulation with recombinant follicle-stimulating hormone and GnRH antagonist cotreatment. J. Clin. Endocrinol. Metab. 88(9), 4186–4192(2003).
Fauser BC, de Jong D, Olivennes F et al. Endocrine profiles after triggering of final oocyte maturation with GnRH agonist after cotreatment with the GnRH antagonist ganirelix during ovarian hyperstimulation for in vitro fertilization. J. Clin. Endocrinol. Metab. 87(2),709–715(2002).
Youssef MA, Van der Veen F, Al-Inany HG et al. Gonadotropin-releasing hormone agonist versus HCG for oocyte triggering in antagonist assisted reproductive technology cycles. Cochrane Database Syst. Rev. 1,CD008046(2011).
Fatemi HM, Popovic-Todorovic B, Papanikolaou E, Donoso P, Devroey P. An update of luteal phase support in stimulated IVF cycles. Hum. Reprod. Update 13(6), 581–590(2007).
Penzias AS. Luteal phase support. Fertil. Steril. 77(2), 318–323(2002).
Pabuccu R, Akar ME. Luteal phase support in assisted reproductive technology. Curr. Opin. Obstet. Gynecol. 17(3), 277–281(2005).
Humaidan P, Papanikolaou EG, Kyrou D et al. The luteal phase after GnRH-agonist triggering of ovulation: present and future perspectives. Reprod. Biomed. Online 24(2),134–141(2012).
Fatemi HM. The luteal phase after 3 decades of IVF: what do we know? Reprod. Biomed. Online 19(Suppl. 4),4331(2009).
van der Linden M, Buckingham K, Farquhar C, Kremer JA, Metwally M. Luteal phase support for assisted reproduction cycles. Cochrane Database Syst. Rev. 10,CD009154(2011).
Nosarka S, Kruger T, Siebert I, Grové D. Luteal phase support in in vitro fertilization: meta-analysis of randomized trials. Gynecol. Obstet. Invest. 60(2), 67–74(2005).
Pritts EA, Atwood AK. Luteal phase support in infertility treatment: a meta-analysis of the randomized trials. Hum. Reprod. 17(9),2287–2299(2002).
Chakravarty BN, Shirazee HH, Dam P, Goswami SK, Chatterjee R, Ghosh S. Oral dydrogesterone versus intravaginal micronised progesterone as luteal phase support in assisted reproductive technology (ART) cycles: results of a randomised study. J. Steroid Biochem. Mol. Biol. 97(5),416–420(2005).
Zarutskie PW, Phillips JA. A meta-analysis of the route of administration of luteal phase support in assisted reproductive technology: vaginal versus intramuscular progesterone. Fertil. Steril. 92(1), 163–169(2009).
Simunic V, Tomic V, Tomic J, Nizic D. Comparative study of the efficacy and tolerability of two vaginal progesterone formulations, Crinone 8% gel and Utrogestan capsules, used for luteal support. Fertil. Steril. 87(1),83–87(2007).
Tay PY, Lenton EA. The impact of luteal supplement on pregnancy outcome following stimulated IVF cycles. Med. J. Malaysia 60(2),151–157(2005).
Leeton J, Trounson A, Jessup D. Support of the luteal phase in in vitro fertilization programs: results of a controlled trial with intramuscular Proluton. J. In Vitro Fert. Embryo Transf. 2(3), 166–169(1985).
Sharara FI, McClamrock HD. Ratio of oestradiol concentration on the day of human chorionic gonadotrophin administration to mid-luteal oestradiol concentration is predictive of in vitro fertilization outcome. Hum. Reprod. 14(11),2777–2782(1999).
Jee BC, Suh CS, Kim SH, Kim YB, Moon SY. Effects of estradiol supplementation during the luteal phase of in vitro fertilization cycles: a meta-analysis. Fertil. Steril. 93(2),428–436(2010).
Kolibianakis EM, Venetis CA, Papanikolaou EG, Diedrich K, Tarlatzis BC, Griesinger G. Estrogen addition to progesterone for luteal phase support in cycles stimulated with GnRH analogues and gonadotrophins for IVF: a systematic review and meta-analysis. Hum. Reprod. 23(6), 1346–1354(2008).
Farhi J, Weissman A, Steinfeld Z, Shorer M, Nahum H, Levran D. Estradiol supplementation during the luteal phase may improve the pregnancy rate in patients undergoing in vitro fertilization–embryo transfer cycles. Fertil. Steril. 73(4),761–766(2000).
Buvat J, Marcolin G, Guittard C, Herbaut JC, Louvet AL, Dehaene JL. Luteal support after luteinizing hormone-releasing hormone agonist for in vitro fertilization: superiority of human chorionic gonadotropin over oral progesterone. Fertil. Steril. 53(3), 490–494(1990).
Tesarik J, Hazout A, Mendoza-Tesarik R, Mendoza N, Mendoza C. Beneficial effect of luteal-phase GnRH agonist administration on embryo implantation after ICSI in both GnRH agonist- and antagonist-treated ovarian stimulation cycles. Hum. Reprod. 21(10),2572–2579(2006).
Pirard C, Donnez J, Loumaye E. GnRH agonist as novel luteal support: results of a randomized, parallel group, feasibility study using intranasal administration of buserelin. Hum. Reprod. 20(7), 1798–1804(2005).
Lambalk CB, Homburg R. GnRH agonist for luteal support in IVF? Setting the balance between enthusiasm and caution. Hum. Reprod. 21(10),2580–2582(2006).
Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil. Steril. 81(1), 19(2004).
Tsilchorozidou T, Overton C, Conway GS. The pathophysiology of polycystic ovary syndrome. Clin. Endocrinol. 60(1),1–17(2004).
Balen AH. Is metformin the treatment of choice for anovulation in polycystic ovary syndrome? Nat. Clin. Pract. Endocrinol. Metab. 3(6),440–441(2007).
The Saloniki ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Consensus on infertility treatment related to polycystic ovary syndrome. Hum. Reprod. 23(3), 462–477(2008).
The Rotterdam EAsPcwg. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum. Reprod. 19(1),41–47(2004).
Griesinger G, Diedrich K, Tarlatzis BC, Kolibianakis EM. GnRH-antagonists in ovarian stimulation for IVF in patients with poor response to gonadotrophins, polycystic ovary syndrome, and risk of ovarian hyperstimulation: a meta-analysis. Reprod. Biomed. Online 13(5),628–638(2006).
Heijnen EM, Eijkemans MJ, Hughes EG, Laven JS, Macklon NS, Fauser BC. A meta-analysis of outcomes of conventional IVF in women with polycystic ovary syndrome. Hum. Reprod. Update 12(1),13–21(2006).
Tso LO, Costello MF, Albuquerque LE, Andriolo RB, Freitas V. Metformin treatment before and during IVF or ICSI in women with polycystic ovary syndrome. Cochrane Database Syst. Rev. 2,CD006105(2009).
Costello MF, Eden JA. A systematic review of the reproductive system effects of metformin in patients with polycystic ovary syndrome. Fertil. Steril. 79(1), 1–13(2003).
Lord J, Flight I, Norman R. Insulin sensitising drugs (metformin, troglitazone, rosiglitazone, pioglitazone, d-chiro-inositol) for polycystic ovary syndrome. Cochrane Database Syst. Rev. 2,CD003053(2003).
Tang T, Glanville J, Orsi N, Barth JH, Balen AH. The use of metformin for women with PCOS undergoing IVF treatment. Hum. Reprod. 21(6),1416–1425(2006).
Swanton A, Lighten A, Granne I et al. Do women with ovaries of polycystic morphology without any other features of PCOS benefit from short-term metformin co-treatment during IVF? A double-blind, placebo-controlled, randomized trial. Hum. Reprod. 26(8),2178–2184(2011).
Van Der Meer M, Hompes PG, De Boer JA, Schats R, Schoemaker J. Cohort size rather than follicle-stimulating hormone threshold level determines ovarian sensitivity in polycystic ovary syndrome. J. Clin. Endocrinol. Metab. 83(2),423–426(1998).
Braat DD, Schutte JM, Bernardus RE, Mooij TM, van Leeuwen FE. Maternal death related to IVF in The Netherlands 1984–2008. Hum. Reprod. 25(7),1782–1786(2010).
Aboulghar MA, Mansour RT, Serour GI, Amin Y. Ultrasonically guided vaginal aspiration of ascites in the treatment of severe ovarian hyperstimulation syndrome. Fertil. Steril. 53(5),933–935(1990).
Aboulghar MA, Mansour RT, Serour GI, Amin YM. Moderate ovarian hyperstimulation syndrome complicated by deep cerebrovascular thrombosis. Hum. Reprod. 13(8), 2088–2091(1998).
Olivennes F. Ovarian hyperstimulation syndrome prevention strategies: individualizing gonadotropin dose. Semin. Reprod. Med. 28(6),463–467(2010).
Marci R, Senn A, Dessole S et al. A low-dose stimulation protocol using highly purified follicle-stimulating hormone can lead to high pregnancy rates in in vitro fertilization patients with polycystic ovaries who are at risk of a high ovarian response to gonadotropins. Fertil. Steril. 75(6), 1131–1135(2001).
Daya S. Updated meta-analysis of recombinant follicle-stimulating hormone (FSH) versus urinary FSH for ovarian stimulation in assisted reproduction. Fertil. Steril. 77(4),711–714(2002).
Pundir J, Sunkara SK, El-Toukhy T, Khalaf Y. Meta-analysis of GnRH antagonist protocols: do they reduce the risk of OHSS in PCOS? Reprod. Biomed. Online 24(1), 6–22(2012).
Cate RL, Mattaliano RJ, Hession C et al. Isolation of the bovine and human genes for Müllerian inhibiting substance and expression of the human gene in animal cells. Cell 45(5),685–698(1986).
Lee MM, Donahoe PK, Hasegawa T et al. Müllerian inhibiting substance in humans: normal levels from infancy to adulthood. J. Clin. Endocrinol. Metab. 81(2),571–576(1996).
Hehenkamp WJ, Looman CW, Themmen AP, de Jong FH, Te Velde ER, Broekmans FJ. Anti-Müllerian hormone levels in the spontaneous menstrual cycle do not show substantial fluctuation. J. Clin. Endocrinol. Metab. 91(10), 4057–4063(2006).
Karkanaki A, Vosnakis C, Panidis D. The clinical significance of anti-Müllerian hormone evaluation in gynecological endocrinology. Hormones (Athens).
van Rooij IA, Tonkelaar I, Broekmans FJ et al. Anti-Müllerian hormone is a promising predictor for the occurrence of the menopausal transition. Menopause 11(6 Pt 1),601–606(2004).
Broer SL, Mol B, Dólleman M, Fauser BC, Broekmans FJ. The role of anti-Müllerian hormone assessment in assisted reproductive technology outcome. Curr. Opin. Obstet. Gynecol. 22(3),193–201(2010).
Broekmans FJ, Kwee J, Hendriks DJ, Mol BW, Lambalk CB. A systematic review of tests predicting ovarian reserve and IVF outcome. Hum. Reprod. Update 12(6), 685–718(2006).
Gnoth C, Schuring AN, Friol K, Tigges J, Mallmann P, Godehardt E. Relevance of anti-Müllerian hormone measurement in a routine IVF program. Hum. Reprod. 23(6), 1359–1365(2008).
Riggs RM, Duran EH, Baker MW et al. Assessment of ovarian reserve with anti-Müllerian hormone: a comparison of the predictive value of anti-Müllerian hormone, follicle-stimulating hormone, inhibin B, and age. Am. J. Obstet. Gynecol. 199(2),202.e1–202.e8(2008).
Jayaprakasan K, Campbell B, Hopkisson J, Johnson I, Raine-Fenning N. A prospective, comparative analysis of anti-Müllerian hormone, inhibin-B, and three-dimensional ultrasound determinants of ovarian reserve in the prediction of poor response to controlled ovarian stimulation. Fertil. Steril. 93(3),855–864(2010).
Nardo LG, Gelbaya TA, Wilkinson H et al. Circulating basal anti-Müllerian hormone levels as predictor of ovarian response in women undergoing ovarian stimulation for in vitro fertilization. Fertil. Steril. 92(5),1586–1593(2009).
Barad DH, Weghofer A, Gleicher N. Comparing anti-Müllerian hormone (AMH) and follicle-stimulating hormone (FSH) as predictors of ovarian function. Fertil. Steril. 91(4),1553(2009).
Lee TH, Liu CH, Huang CC et al. Serum anti-Müllerian hormone and estradiol levels as predictors of ovarian hyperstimulation syndrome in assisted reproduction technology cycles. Hum. Reprod. 23(1), 160–167(2008).
Aflatoonian A, Oskouian H, Ahmadi S, Oskouian L. Prediction of high ovarian response to controlled ovarian hyperstimulation: anti-Müllerian hormone versus small antral follicle count (2–6?mm).
Nelson SM, Yates RW, Lyall H et al. Anti-Müllerian hormone-based approach to controlled ovarian stimulation for assisted conception. Hum. Reprod. 24(4), 867–875(2009).
Duffy JM, Ahmad G, Mohiyiddeen L, Nardo LG, Watson A. Growth hormone for in vitro fertilization. Cochrane Database Syst. Rev. 1, CD000099(2010).
Yoshimura Y, Ando M, Nagamatsu S et al. Effects of insulin-like growth factor-I on follicle growth, oocyte maturation, and ovarian steroidogenesis and plasminogen activator activity in the rabbit. Biol. Reprod. 55(1),152–160(1996).
Blumenfeld Z, Amit T. The role of growth hormone (GH), GH-receptor and GH-binding protein in reproduction and ovulation induction. J. Pediatr. Endocrinol. Metab. 9(2),145–162(1996).
Mason HD, Martikainen H, Beard RW, Anyaoku V, Franks S. Direct gonadotrophic effect of growth hormone on oestradiol production by human granulosa cells in vitro . J. Endocrinol. 126(3),R1–R4(1990).
Homburg R, Eshel A, Abdalla HI, Jacobs HS. Growth hormone facilitates ovulation induction by gonadotrophins. Clin. Endocrinol. (Oxf) . 29(1), 113–117(1988).
Homburg R, West C, Torresani T, Jacobs HS. Cotreatment with human growth hormone and gonadotropins for induction of ovulation: a controlled clinical trial. Fertil. Steril. 53(2),254–260(1990).
Dor J, Seidman DS, Amudai E, Bider D, Levran D, Mashiach S. Adjuvant growth hormone therapy in poor responders to in vitro fertilization: a prospective randomized placebo-controlled double-blind study. Hum. Reprod. 10(1),40–43(1995).
Kolibianakis EM, Venetis CA, Diedrich K, Tarlatzis BC, Griesinger G. Addition of growth hormone to gonadotrophins in ovarian stimulation of poor responders treated by in vitro fertilization: a systematic review and meta-analysis. Hum. Reprod. Update 15(6), 613–622(2009).
Harper K, Proctor M, Hughes E. Growth hormone for in vitro fertilization. Cochrane Database Syst. Rev. 3,CD000099(2003).
Casson PR, Lindsay MS, Pisarska MD, Carson SA, Buster JE. Dehydroepiandrosterone supplementation augments ovarian stimulation in poor responders: a case series. Hum. Reprod. 15(10),2129–2132(2000).
Buster JE, Casson PR, Straughn AB et al. Postmenopausal steroid replacement with micronized dehydroepiandrosterone: preliminary oral bioavailability and dose proportionality studies. Am. J. Obstet. Gynecol. 166(4),1163–1168; discussion 1168(1992).
Casson PR, Santoro N, Elkind-Hirsch K et al. Postmenopausal dehydroepiandrosterone administration increases free insulin-like growth factor-I and decreases high-density lipoprotein: a six-month trial. Fertil. Steril. 70(1),107–110(1998).
Gleicher N, Barad DH. Dehydroepiandrosterone (DHEA) supplementation in diminished ovarian reserve (DOR).
Wiser A, Gonen O, Ghetler Y, Shavit T, Berkovitz A, Shulman A. Addition of dehydroepiandrosterone (DHEA) for poor-responder patients before and during IVF treatment improves the pregnancy rate: a randomized prospective study. Hum. Reprod. 25(10),2496–2500(2010).
Barad D, Gleicher N. Effect of dehydroepiandrosterone on oocyte and embryo yields, embryo grade and cell number in IVF. Hum. Reprod. 21(11),2845–2849(2006).
Bosdou JK, Venetis CA, Kolibianakis EM et al. The use of androgens or androgen-modulating agents in poor responders undergoing in vitro fertilization: a systematic review and meta-analysis. Hum. Reprod. Update 18(2),127–145(2012).
Sen A, Hammes SR. Granulosa cell-specific androgen receptors are critical regulators of ovarian development and function. Mol. Endocrinol. 24(7),1393–1403(2010).
Kroboth PD, Salek FS, Pittenger AL, Fabian TJ, Frye RF. DHEA and DHEA-S: a review. J. Clin. Pharmacol. 39(4),327–348(1999).

Website
201. Clinicaltrials.gov. A trial of Dehydroepiandrosterone (DHEA) treatment for in vitro fertilization (IVF). http://clinicaltrials.gov/ct2/show/NCT00419913

As an organization accredited by the ACCME, Medscape, LLC, requires everyone who is in a position to control the content of an education activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines "relevant financial relationships" as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest.

Medscape, LLC, encourages Authors to identify investigational products or off-label uses of products regulated by the US Food and Drug Administration, at first mention and where appropriate in the content.

Author(s)

Chun Ng, MRCOG

Consultant in Reproductive Medicine and Surgery, Hammersmith Hospital, London, United Kingdom

Disclosures

Disclosure: Chun Ng, MRCOG, has disclosed no relevant financial relationships.

Geoffrey Trew, MRCOG

Consultant in Reproductive Medicine and Surgery, Hammersmith Hospital, London, United Kingdom

Disclosures

Disclosure: Geoffrey Trew, MRCOG, has disclosed no relevant financial relationships.

Editor

Elisa Manzotti

Publisher, Future Science Group, London, United Kingdom

Disclosures

Disclosure: Elisa Manzotti has disclosed no relevant financial relationships.

CME Author

Charles P. Vega, MD

Health Sciences Clinical Professor; Residency Director, Department of Family Medicine, University of California, Irvine

Disclosures

Disclosure: Charles P. Vega, MD, FAAFP, has disclosed no relevant financial relationships.

CME Reviewer

Nafeez Zawahir, MD

CME Clinical Director, Medscape, LLC

Disclosures

Disclosure: Nafeez Zawahir, MD, has disclosed no relevant financial relationships.

CME

Endocrinological Insights Into Different in vitro Fertilization Treatment Aspects

Authors: Chun Ng, MRCOG; Geoffrey Trew, MRCOG
CME Released: 7/30/2012
THIS ACTIVITY HAS EXPIRED
Valid for credit through: 7/30/2013

Start Activity

Target Audience and Goal Statement

This activity is intended for endocrinologists, obstetrician gynecologists, and other physicians who care for women with infertility.

The goal of this activity is to evaluate endocrine issues in IVF.

Upon completion of this activity, participants will be able to:

Compare the use of gonadotropin-releasing hormone agonists and antagonists in IVF
Analyze the use of gonadotropins in IVF
Assess treatment of the luteal phase during IVF
Evaluate other endocrine issues in IVF

Disclosures

Author(s)

Chun Ng, MRCOG

Consultant in Reproductive Medicine and Surgery, Hammersmith Hospital, London, United Kingdom

Disclosures

Disclosure: Chun Ng, MRCOG, has disclosed no relevant financial relationships.

Geoffrey Trew, MRCOG

Consultant in Reproductive Medicine and Surgery, Hammersmith Hospital, London, United Kingdom

Disclosures

Disclosure: Geoffrey Trew, MRCOG, has disclosed no relevant financial relationships.

Editor

Elisa Manzotti

Publisher, Future Science Group, London, United Kingdom

Disclosures

Disclosure: Elisa Manzotti has disclosed no relevant financial relationships.

CME Author

Charles P. Vega, MD

Health Sciences Clinical Professor; Residency Director, Department of Family Medicine, University of California, Irvine

Disclosures

Disclosure: Charles P. Vega, MD, FAAFP, has disclosed no relevant financial relationships.

CME Reviewer

Nafeez Zawahir, MD

CME Clinical Director, Medscape, LLC

Disclosures

Disclosure: Nafeez Zawahir, MD, has disclosed no relevant financial relationships.

Accreditation Statements

For Physicians

This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of Medscape, LLC and Expert Reviews Ltd. Medscape, LLC is accredited by the ACCME to provide continuing medical education for physicians.

Medscape, LLC designates this Journal-based CME activity for a maximum of 1.00 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Medscape, LLC staff have disclosed that they have no relevant financial relationships.

Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]

Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 70% on the post-test.

Follow these steps to earn CME/CE credit*:

Read the target audience, learning objectives, and author disclosures.
Study the educational content online or printed out.
Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. Medscape Education encourages you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates by accessing "Edit Your Profile" at the top of your Medscape homepage.

*The credit that you receive is based on your user profile.

processing....

Abstract

The science of reproductive endocrinology/in vitro fertilization (IVF) has moved forward considerably since the first IVF baby was born in 1978. IVF was originally indicated for women with tubal factor infertility, but it has now become the treatment for couples with unexplained subfertility, male subfertility, cervical factor, failed ovulation induction, endometriosis or unilateral tubal pathology. IVF was initially performed with the single dominant ovarian follicle produced during a spontaneous menstrual cycle. This was very inefficient and pregnancy rates were dismal. Consequently, superovulation protocols using parenteral gonadotrophins to induce maturation of multiple follicles were soon adopted worldwide. In addition, any supernumerary embryos remaining after embryo transfer may be cryopreserved for future embryo transfers without the need for another fresh IVF cycle. A greater understanding of IVF endocrinology has led to improved IVF pregnancy outcomes and satisfaction for the anxious parents. However, with the greater success of IVF treatment, new complications associated with the treatment arise, namely the ovarian hyperstimulation syndrome. Ovarian hyperstimulation can be associated with severe morbidity and may be even fatal. Ovarian hyperstimulation syndrome is an iatrogenic condition secondary to medical stimulation of the ovary, and was virtually unknown until IVF treatment was initiated. This article will discuss the recent developments in IVF treatment endocrinology and protocols, as well as prevention/treatment of its complications.

Page 1 of 16

IVF Protocols Using Gonadotrophin-releasing Hormone Agonist

CME Information

References

References

Disclaimer

The material presented here does not necessarily reflect the views of Medscape, LLC, or companies that support educational programming on medscape.org. These materials may discuss therapeutic products that have not been approved by the US Food and Drug Administration and off-label uses of approved products. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity.

References

Faculty and Disclosures

Author(s)

Chun Ng, MRCOG

Geoffrey Trew, MRCOG

Editor

Elisa Manzotti

CME Author

Charles P. Vega, MD

CME Reviewer

Nafeez Zawahir, MD

CME

Endocrinological Insights Into Different in vitro Fertilization Treatment Aspects

Target Audience and Goal Statement

Disclosures

Author(s)

Chun Ng, MRCOG

Geoffrey Trew, MRCOG

Editor

Elisa Manzotti

CME Author

Charles P. Vega, MD

CME Reviewer

Nafeez Zawahir, MD

Accreditation Statements

For Physicians

Instructions for Participation and Credit

Endocrinological Insights Into Different in vitro Fertilization Treatment Aspects

Abstract

Table of Contents